Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
Blood|April 1, 1993
Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignanciesS N Rabinowe, D Neuberg, P J Bierman, et al.
The New England Journal of Medicine|June 20, 1991
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancerJ Nemunaitis, S N Rabinowe, J W Singer, et al.
Blood|June 15, 1994
Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemiaJ Nemunaitis, F R Appelbaum, K Lilleby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1992
Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myelomaW I Bensinger, C D Buckner, R A Clift, et al.
Leukemia|July 1, 1993
Clonal remission in childhood acute myeloid leukemia is an infrequent eventF O Smith, W H Raskind, P Waldron, et al.
Blood|October 1, 1993
A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantationR A Clift, J A Bianco, F R Appelbaum, et al.
Critical Care Medicine|July 1, 1996
An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndromeS L Bursten, D A Federighi, P Parsons, et al.
Bone Marrow Transplantation|February 16, 2000
A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study GroupA F List, R Maziarz, P Stiff, et al.
British Journal of Cancer|May 14, 2008
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancerL Paz-Ares, H Ross, M O'Brien, et al.
Pageof 19